Hemostemix Inc. has moved to its new head office in The Edison building in Calgary, Alberta, Canada and made several executive appointments.
The company ended its CEO search by promoting Kyle Makofka from chief restructuring officer to president and CEO. It also appointed Kristin Gulka as CFO to replace David Berman, who has stepped down and will operate in an advisory capacity until the transition is complete.
Gulka previously worked for 3 years at SemBioSys Genetics Inc.
In addition, Ravi Jain, who previously worked as a consultant to the company, has been named chief scientific officer. Jain was most recently the managing director at UC Santa Cruz Genomics Institute.
Concurrently, Hemostemix is also transitioning its stem cell manufacturing operations to a third party supplier in North America in order to improve efficiency and logistics.
This transition will save the company more than C$500,000 per year and improve logistical support for the company's current North American focused clinical trial activities for patients with critical limb ischemia, a severe form of peripheral artery disease caused by reduced blood flow to the legs.
